A detailed history of Gw&K Investment Management, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Gw&K Investment Management, LLC holds 1,394,196 shares of ITCI stock, worth $119 Million. This represents 0.87% of its overall portfolio holdings.

Number of Shares
1,394,196
Previous 1,393,978 0.02%
Holding current value
$119 Million
Previous $95.5 Million 6.85%
% of portfolio
0.87%
Previous 0.87%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$67.99 - $80.84 $14,821 - $17,623
218 Added 0.02%
1,394,196 $102 Million
Q2 2024

Aug 12, 2024

SELL
$64.76 - $79.84 $13.3 Million - $16.4 Million
-204,986 Reduced 12.82%
1,393,978 $95.5 Million
Q1 2024

May 08, 2024

SELL
$64.37 - $75.65 $1.88 Million - $2.22 Million
-29,280 Reduced 1.8%
1,598,964 $111 Million
Q4 2023

Feb 09, 2024

SELL
$46.37 - $73.65 $2.96 Million - $4.7 Million
-63,836 Reduced 3.77%
1,628,244 $117 Million
Q3 2023

Nov 09, 2023

SELL
$52.09 - $64.1 $1.83 Million - $2.26 Million
-35,207 Reduced 2.04%
1,692,080 $88.1 Million
Q2 2023

Aug 09, 2023

SELL
$54.67 - $66.44 $1.41 Million - $1.71 Million
-25,780 Reduced 1.47%
1,727,287 $109 Million
Q1 2023

May 09, 2023

BUY
$43.8 - $56.99 $13.3 Million - $17.3 Million
302,685 Added 20.87%
1,753,067 $94.9 Million
Q4 2022

Feb 10, 2023

SELL
$44.07 - $54.45 $681,013 - $841,415
-15,453 Reduced 1.05%
1,450,382 $76.8 Million
Q3 2022

Nov 09, 2022

BUY
$42.7 - $59.99 $37.7 Million - $52.9 Million
882,242 Added 151.17%
1,465,835 $68.2 Million
Q2 2022

Aug 09, 2022

BUY
$43.0 - $65.64 $1.47 Million - $2.25 Million
34,266 Added 6.24%
583,593 $33.3 Million
Q1 2022

May 09, 2022

BUY
$38.74 - $62.09 $6.82 Million - $10.9 Million
176,007 Added 47.15%
549,327 $33.6 Million
Q4 2021

Feb 11, 2022

BUY
$35.2 - $53.42 $13.1 Million - $19.9 Million
373,320 New
373,320 $19.5 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.09B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Gw&K Investment Management, LLC Portfolio

Follow Gw&K Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gw&K Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gw&K Investment Management, LLC with notifications on news.